Saturday, August 2, 2025 8/2/2025

Differentiation of Granulocytes and Macrophages

Award Number: R37CA022556
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 03/01/1978
PERIOD OF PERFORMANCE END DATE: 07/31/2015

Group Awards By:

View Award Description

Differentiation of Granulocytes and Macrophages - Cytokines are secreted regulators that control the production, maturation and functional activation of blood cells that are essential for hemostasia and host defense from infection. These beneficial actions of cytokines have been harnessed clinically, for example the use of G-CSF to promote recovery of white blood cells in patients receiving cancer chemotherapy, or EPO to treat anemia. In addition, deregulation of cytokines, their receptors or intracellular signal transduction pathways is associated with autoimmunity and cancer. The importance of negative regulation of cytokine signaling cascades has come clearly into focus with our identification and characterization of the family of Suppressors of Cytokine Signaling (SOCS) proteins. Our long-term objective is to identify the specific cytokines regulated by individual SOCS proteins and the cells and biological systems dependent on SOCS regulation. We seek to define the biochemical basis of SOCS action via elucidation of the structures of, and physical interactions between, SOCS proteins and the signaling machinery and to define the disease contexts in which manipulation of SOCS proteins may prove clinically beneficial. Our focus here is on S0CS3, the key negative regulator of G-CSF and IL-6 that is required to prevent spontaneous inflammatory disease. Applying a multidlsciplinary approach employing biochemical and structural biological tools, cell biology and genetically modified mouse models, our major goals are: defining the specific roles of S0CS3 in relevant mouse models of inflammation and hematopoietic malignancy, understanding the shared or overlapping physiological roles of S0CS3 with other SOCS family members, and defining the functions of protein domains within the overall actions of S0CS3, along with discovery of novel protein targets of S0CS3 action. RELEVANCE (See instructions): Successful outcomes will provide new strategies for intervention in cytokine-related diseases, particularly cancer and inflammation.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2014 ( Subtotal = $223,296 )
2014	2014	WALTER & ELIZA HALL INSTITUTE OF MEDICAL RESEARCH	1G ROYAL PDE	PARKVILLE VICTORIA				AUS	Cancer Biology Research	000	36	7/29/2014	NON-COMPETING CONTINUATION	$223,296
														Subtotal = $223,296

Issue Date FY: 2013 ( Subtotal = $216,389 )
2013	2013	WALTER & ELIZA HALL INSTITUTION OF MEDICINE	ROYAL MELBOURNE HOSPITAL	MELBOURNE				AUS	Cancer Biology Research	000	35	7/30/2013	EXTENSION WITH OR WITHOUT FUNDS	$216,389
														Subtotal = $216,389

Issue Date FY: 2012 ( Subtotal = $230,201 )
2012	2012	WALTER & ELIZA HALL INSTITUTION OF MEDICINE	ROYAL MELBOURNE HOSPITAL	MELBOURNE				AUS	Cancer Biology Research	000	34	7/27/2012	NON-COMPETING CONTINUATION	$230,201
														Subtotal = $230,201

Issue Date FY: 2011 ( Subtotal = $230,201 )
2011	2011	WALTER & ELIZA HALL INSTITUTION OF MEDICINE	ROYAL MELBOURNE HOSPITAL	MELBOURNE				AUS	Cancer Biology Research	000	33	7/22/2011	NON-COMPETING CONTINUATION	$230,201
														Subtotal = $230,201

Issue Date FY: 2010 ( Subtotal = $237,320 )
2010	2010	WALTER & ELIZA HALL INSTITUTION OF MEDICINE	ROYAL MELBOURNE HOSPITAL	MELBOURNE				AUS	Cancer Biology Research	000	32	6/14/2010	EXTENSION WITH OR WITHOUT FUNDS	$237,320
														Subtotal = $237,320

Issue Date FY: 2009 ( Subtotal = $230,408 )
2009	2009	WALTER & ELIZA HALL INSTITUTION OF MEDICINE	ROYAL MELBOURNE HOSPITAL	MELBOURNE				AUS	Cancer Biology Research	000	31	7/8/2009	NON-COMPETING CONTINUATION	$230,408
														Subtotal = $230,408

Issue Date FY: 2008 ( Subtotal = $230,408 )
2008	2008	WALTER & ELIZA HALL INSTITUTION OF MEDICINE	ROYAL MELBOURNE HOSPITAL	MELBOURNE		00000		AUS	Cancer Biology Research	000	30	7/24/2008	NON-COMPETING CONTINUATION	$230,408
														Subtotal = $230,408

Issue Date FY: 2007 ( Subtotal = $230,408 )
2007	2007	WALTER & ELIZA HALL INSTITUTION OF MEDICINE	ROYAL MELBOURNE HOSPITAL	MELBOURNE		00000		AUS	Cancer Biology Research	000	29	7/12/2007	NON-COMPETING CONTINUATION	$230,408
														Subtotal = $230,408

Issue Date FY: 2006 ( Subtotal = $237,290 )
2006	2006	WALTER & ELIZA HALL INSTITUTION OF MEDICINE	ROYAL MELBOURNE HOSPITAL	MELBOURNE		00000		AUS	Cancer Biology Research	000	28	7/28/2006	NON-COMPETING CONTINUATION	$237,290
														Subtotal = $237,290

Issue Date FY: 2005 ( Subtotal = $243,000 )
2005	2005	WALTER & ELIZA HALL INSTITUTION OF MEDICINE	ROYAL MELBOURNE HOSPITAL	MELBOURNE		00000		AUS	Cancer Biology Research	000	27	7/29/2005	COMPETING CONTINUATION	$243,000
														Subtotal = $243,000

Grand Total All Awards = $2,308,921

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Differentiation of Granulocytes and Macrophages

Award Number: R37CA022556

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 03/01/1978

PERIOD OF PERFORMANCE END DATE: 07/31/2015

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer